Vamsi Kanagala, MD
Internal Medicine · Monroe, GANPI 1952712788
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $169 of the $270 with a category attached, or 62.5%. Acadia Pharmaceuticals Inc accounts for 62.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in GA, where the typical reported total is $311.
Across 3 payments — averaging $90.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$169
- Teva Pharmaceuticals USA, Inc.$101
What the payments were for
- Food & beverage$16962%
- Education$10138%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 2 | $169 |
| Teva Pharmaceuticals USA, Inc. | 1 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$102
How this compares
$270 in reported general payments places this provider in the 45th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 848 | $302,872 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,407 |
| JardianceEmpagliflozin | 149 | $45,429 |
| XareltoRivaroxaban | 112 | $35,254 |
| FarxigaDapagliflozin Propanediol | 94 | $29,573 |
| GlatopaGlatiramer Acetate | 15 | $28,488 |
| EntrestoSacubitril/Valsartan | 72 | $25,745 |
| OzempicSemaglutide | 24 | $24,272 |
| MyrbetriqMirabegron | 80 | $22,680 |
| LinzessLinaclotide | 41 | $22,017 |
| JanuviaSitagliptin Phosphate | 75 | $21,681 |
| Potassium Chloride | 395 | $18,620 |
| Memantine Hcl | 486 | $17,570 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 56 | $17,423 |
| RocklatanNetarsudil Mesylat/Latanoprost | 47 | $17,286 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Monroe
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.